

Atypical Antipsychotics Step Therapy with Quantity Limit Program Summary

Step Therapy applies to FlexRx Open, FocusRx, GenRx Open, Health Insurance Marketplace, and KeyRx formularies.

This is a FlexRx Standard and GenRx Standard program.

The BCBS MN Step Therapy Supplement also applies to this program for all Commercial/HIM lines of business.

Quantity limits apply to FlexRx Closed, FlexRx Open, FocusRx, GenRx Closed, GenRx Open, Health Insurance Marketplace, and KeyRx.

POLICY REVIEW CYCLE

Effective Date06-01-2024

Date of Origin
01-01-2021

FDA APPROVED INDICATIONS AND DOSAGE

Agent(s)	FDA Indication(s)	Notes	Ref#
Abilify Mycite® (aripiprazole) Tablet with sensor, strips, and pod (Starter kit) Tablet with sensor and strips (Maintenance kit)	Treatment of: Schizophrenia Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Disorder Adjunctive Treatment of Major Depressive Disorder Irritability Associated with Autistic Disorder Tourette's Disorder		34
Abilify®	Treatment of:	*generic available	6
(aripiprazole) * Tablet	 Schizophrenia Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Disorder Adjunctive Treatment of Major Depressive Disorder Irritability Associated with Autistic Disorder 		
Oral solution	Tourette's Disorder		
Orally disintegrating tablet			
Caplyta®	-Schizophrenia in adults		36
(lumateperon e)	-Depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults, as monotherapy and as adjunctive therapy with lithium or valproate.		
Capsule			

Agent(s)	FDA Indication(s)	Notes	Ref#
Clozapine	- Treatment-resistant schizophrenia	*generic available	1; 15
ODT, Clozaril®	- Reducing suicidal behavior in patients with schizophrenia or schizoaffective disorder	^12.5mg ODT brand name only	
(clozapine)	Schizouricetve district.	maine only	
Tablet*			
Orally disintegrating tablet*^			
Fanapt®	Treatment of schizophrenia		10
(iloperidone)			
Tablet			
Geodon®	- Treatment of schizophrenia	*generic available	5
(ziprasidone)	- Acute treatment as monotherapy of manic or mixed episodes associated with bipolar I disorder		
Capsule*	- Maintenance treatment of bipolar I disorder as an adjunct to lithium or valproate		
Invega ER®	- Treatment of schizophrenia	*generic available	7
(paliperidone ER)	- Treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers and/or antidepressants		
Tablet*			
Latuda®	Treatment of:		11
(lurasidone) Tablet*	 Schizophrenia Depressive Episodes associated with Bipolar I Disorder (bipolar depression), as monotherapy and as adjunctive therapy with lithium or valproate 		
Lybalvi®	- Schizophrenia in adults		37
(olanzapine- samidorphan)	- Bipolar I disorder in adults		
Tablet	 Acute treatment of manic or mixed episodes as monotherapy and as adjunct to lithium or valproate Maintenance monotherapy treatment 		
Rexulti®	- Treatment of schizophrenia in adults and pediatric patients ages 13 years and older		14
(brexpiprazole)	- Use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD)		
Tablet	- Treatment of agitation associated with dementia due to Alzheimer's disease		

Agent(s)	FDA Indication(s)	Notes	Ref#
	Limitation of Use: Rexulti is not indicated as an as needed ("prn") treatment for agitation associated with dementia due to Alzheimer's disease		
Risperdal®, Risperidone	- Treatment of schizophrenia	*generic available	2
ODT (risperidone)	- As monotherapy or adjunctive therapy with lithium or valproate, for the treatment of acute manic or mixed episodes associated with Bipolar I Disorder	^0.25mg tablet brand name only	
Tablet*	- Treatment of irritability associated with autistic disorder		
Orally disintegrating tablet*^			
Oral solution*			
Saphris®	- Treatment of schizophrenia	*generic available	9
(asenapine)	- Bipolar I disorder		
Sublingual tablet*	- Acute monotherapy treatment of manic or mixed episodes, in adults and pediatric patients 10 to 17 years of age		
	- Adjunctive treatment to lithium or valproate in adults		
	- Maintenance monotherapy treatment in adults		
Secuado®	- Treatment of schizophrenia		35
(asenapine)			
Transdermal system			
Seroquel®	- Treatment of schizophrenia	*generic available	4
(quetiapine)	- Bipolar I disorder manic episodes		
Tablet*	- Bipolar disorder, depressive episodes		
Seroquel XR®	- Treatment of schizophrenia	*generic available	8
(quetiapine)	- Bipolar I disorder, manic, or mixed episodes		
Tablet*	- Bipolar disorder, depressive episodes		
	- Major depressive disorder, adjunctive therapy with antidepressants		
Versacloz®	- Treatment-resistant schizophrenia.		13
(clozapine)	- Reducing suicidal behavior in patients with schizophrenia or schizoaffective disorder		
Oral suspension			
Vraylar®	- Treatment of schizophrenia in adults		15

Agent(s)	FDA Indication(s)	Notes	Ref#
Capsule	- Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults		
	- Treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults		
	- Adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults		
Zyprexa®, Zyprexa® Zy	- Treatment of schizophrenia	*generic available	3
dis® (olanzapine)*	- Acute treatment of manic or mixed episodes associated with bipolar I disorder and maintenance treatment of bipolar I disorder		
Tablet	- Adjunct to valproate or lithium in the treatment of manic or mixed episodes associated with bipolar I disorder.		
Orally disintegrating			
tablet	As ZYPREXA and fluoxetine in combination for the:		
	Treatment of depressive episodes associated with bipolar I disorder.		
	Treatment of treatment resistant depression (major depressive disorder in patients who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode		

See package insert for FDA prescribing information: https://dailymed.nlm.nih.gov/dailymed/index.cfm

CLINICAL RATIONALE

Schizophrenia	Schizophrenia is a psychiatric disorder that involves chronic or recurrent psychosis. Antipsychotic medications are first-line treatment for schizophrenia. Antipsychotics have been shown to reduce positive symptoms of schizophrenia, such as hallucinations, delusions, and suspiciousness. Negative symptoms of schizophrenia, such as diminished emotional expression and lack of motivation, have proven particularly difficult to treat. Clozapine is generally considered the most effective antipsychotic drug for the treatment of schizophrenia. Due to adverse effects such as agranulocytosis and seizures, it's use is reserved for patients with treatment-resistant disease, suicide risk, or risk of aggressive behavior despite other treatments. Antipsychotic medications are commonly grouped into two categories, with "second-generation" or "atypical" applied to clozapine and all antipsychotics first marketed after clozapine was approved in 1989, and "first-generation" applied to all antipsychotics marketed previously. Atypical antipsychotics tend to cause fewer extrapyramidal side effects than first generation antipsychotics. Elderly patients, in particular, are at increased risk of chronic confusion and disorientation during treatment with first generation antipsychotic drugs.(16,17)
Bipolar Disorder	Bipolar disorder is a mood disorder that is characterized by episodes of mania, hypomania, and major depression. Initiation of maintenance therapy is recommended to prevent relapse, minimize suicide attempts, and maybe associated with reduced rates of violent behavior. First line maintenance therapy is recommended, if possible, to consist of the same regimen that successfully treated the acute bipolar mood episode. Lithium, quetiapine, divalproex, and lamotrigine monotherapy are considered first-line treatments. Second line therapy is reserved for those who do not tolerate first-line maintenance pharmacotherapy. Olanzapine, risperidone, carbamazepine, paliperidone, ziprasidone, and lurasidone are all considered second-line therapies.(18,19)

Major Donuscius Diservice	Marie de mareira disculso (MDD) e las los estados de la deservición de la deservición de la defensa de la deservición de la defensa de la defe
Major Depressive Disorder	Major depressive disorder (MDD), also known as unipolar major depression, is diagnosed when a patient has suffered at least one major depressive episode and have no history of mania or hypomania. Goal of initial treatment for depression is symptom remission and restoring baseline functioning. Selective serotonin reuptake inhibitors (SSRIs) along with serotonin norepinephrine reuptake inhibitors (SNRIs), bupropion, and mirtazapine are considered first line treatment options for adults with major depressive disorder (MDD). Guidelines do not consider antipsychotics as a first line treatment of major depressive disorder without psychosis. However, they suggest that psychotic depression typically responds better to the combination of an antipsychotic and an antidepressant medication rather than either component alone, although some research has shown comparable responses for anti-depressive treatment or antipsychotic treatment alone.(20,21)
Autism	Practice Parameters-American Academy of Child and Adolescent Psychiatry (AACAP, 2014) suggest pharmacotherapy may be offered when there is a specific target symptom or comorbid condition, potentially increasing patient ability to profit from educational and other interventions, and allow less restrictive environments through management of severe and challenging behaviors. Frequent targets for pharmacologic intervention include associated comorbid conditions (e.g., anxiety, depression) and other features (e.g., aggression, self-injurious behavior, hyperactivity, inattention, compulsive-like behaviors, repetitive or stereotypic behaviors, and sleep disturbances). Various considerations (e.g., adverse effects) should inform pharmacologic treatment. Risperidone and aripiprazole have been FDA approved for the treatment of irritability (e.g., physical aggression, severe tantrum behavior) associated with autism. There is a growing body of controlled evidence for pharmacologic intervention. The guideline provides a summary chart of medications supported by RCTs for use in children with autism spectrum disorder (ASD), including target symptoms, ages, dosing, potential adverse effects, and outcomes.
	 Antipsychotics supported by RCTs showing positive effects on various target symptoms in ASD include aripiprazole, haloperidol, olanzapine, and risperidone. Combining medication with parent training is moderately more efficacious than medication alone for decreasing serious behavioral disturbance and modestly more efficacious for adaptive functioning. Individuals with ASD may be nonverbal, so treatment response is often judged by caregiver report and observation of specific behaviors. Although this may help document the effectiveness of the selected medication, an overall goal of treatment is to facilitate the child's adjustment and engagement with educational intervention.
	Despite many randomized trials, confidence in reported improvements remains low for most interventions. Risperidone and aripiprazole improved challenging behavior in the short term (less than 6 months) but also significant harms including weight gain, appetite changes, and EPS.(22,23)
Dementia-Related Psychosis (off- label use)	The American Psychiatric Association (APA) recommends that nonpharmacologic interventions be attempted before a trial of antipsychotic drug therapy and that the interventions attempted be guided by the patient's level of distress and the risk to the patients and caregiver. In addition, the FDA states that physicians who prescribe antipsychotics to elderly patients with dementia-related psychosis should discuss the risk of increased mortality with their patients, patients' families, and caregivers. Evidence indicates that antipsychotics provide weak benefits for the treatment of psychosis and agitation in patients with dementia. Adverse effects of antipsychotics include sedation, metabolic effects, and cognitive impairment. For many patients with Alzheimer's disease, antipsychotics can be tapered and discontinued without significant signs of withdrawal or return of behavioral symptoms.
	Antipsychotic drug therapy generally is reserved for patients who have severe symptoms or when associated agitation, combativeness, or violent behavior puts the patient or others in danger. Current evidence indicates that the atypical antipsychotics can provide modest improvement in behavioral manifestations; some evidence suggests that efficacy may be better for psychosis than for other manifestations. Antipsychotic efficacy appears to be similar among available agents and therefore the

	choice of agent should be based on adverse effect profile and other patient considerations; to minimize adverse effects, the lowest possible effective dose should be used.(24,25)
Tourette's Disorder	Tourette's disorder is a neuropsychiatric disorder characterized by involuntary motor and vocal tics. Although the etiology of Tourette's disorder is unknown, evidence suggests that pathophysiology of this disorder involves an abnormality in the central dopaminergic system. Currently, the medications that are FDA approved for the treatment of Tourette's disorder are aripiprazole, haloperidol, and pimozide although most clinicians use atypical antipsychotics prior to the two approved agents. Clonidine and guanfacine are considered first line agents due to their low side effect profile. However, the level of evidence for their effectiveness is less than antipsychotics and they lack an FDA approval. Atypical neuroleptics (aripiprazole or risperidone) are typically used if the alpha-2 agonists are ineffective or intolerable.
	According to the American Academy of Neurology guidelines, there was moderate confidence that haloperidol, risperidone, aripiprazole, tiapride, clonidine, onabotulinumtoxin A injections were probably more likely than placebo to reduce tics. There was low confidence that pimozide, ziprasidone, metoclopramide, guanfacine, topiramate, and tetrahydrocannabinol were possibly more likely than placebo to reduce tics. There is high confidence that the patients need to be counseled and monitored for adverse events such as weight gain, drug-induced movement disorders, elevated prolactin levels, sedation, and effects on the heart rate, blood pressure, and ECGs. The class of medicine is selected based on the severity of the tics and the side effect profile of the medicine based on other comorbidities such as depression, anxiety, and sleep disturbance. The American Academy of Child & Adolescent Psychiatry states that atypical antipsychotics are effective in Tourette's Disorder (TD). At the time the guidelines were published, no atypical antipsychotics were FDA approved, and only haloperidol and pimozide had been approved for TD. The guidelines found that risperidone is the most well studied non-FDA labeled atypical antipsychotic for the treatment of TD. Risperidone was found to be at least as effective as clonidine, haloperidol, and pimozide; with less frequent and severe side effects. The most common adverse reaction with risperidone therapy was mild to moderate sedation. No clinically significant extrapyramidal symptoms were observed.(26-29)
Safety	The atypical antipsychotic agents carry a boxed warning for increased mortality in elderly patients with dementia-related psychosis. The warning states that elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. These agents are not approved for the treatment of patients with dementia-related psychosis.(1-15,30-33)
	Abilify, Caplyta, Latuda, Rexulti, Risperdal, and Seroquel/Seroquel XR have an additional boxed warning for an increased risk of suicidal thoughts and behaviors in pediatric and young adult patients. Closely monitor all antidepressant-treated patients for worsening and emergence of suicidal thoughts and behaviors.(2,4,6,8,11,14,30,32)
	All clozapine agents including Versacloz, have the following boxed warnings:(1,12,13)
	 Severe Neutropenia: Clozaril can cause severe neutropenia, which can lead to serious and fatal infections. Patients initiating and continuing treatment with Clozaril must have a baseline blood absolute neutrophil count (ANC) measured before treatment initiation and regular ANC monitoring during treatment. Clozaril is available only through a restricted program called the Clozapine Risk Evaluation and Mitigation Strategy (REMS). Orthostatic Hypotension, Bradycardia, and Syncope: Risk is dose related. Starting dose is 12.5 mg. Titrate gradually and use divided dosages. Seizure: Risk is dose related. Titrate gradually and use divided doses. Use with caution in patients with history of seizure or risk factors for seizure. Myocarditis, Cardiomyopathy and Mitral Valve Incompetence: Can be fatal. Discontinue and obtain cardiac evaluation if findings suggest these cardiac reactions.

reactions.

Increased Mortality in Elderly Patients with Dementia-Related Psychosis: Clozaril is not approved for this condition.

REFERENCES

	<u>ENCES</u>
	Reference
1	Clozaril tablets prescribing information. Novartis Pharmaceuticals Co. May 2023.
2	Risperdal prescribing information. Janssen Pharmaceuticals, Inc. December 2022.
3	Zyprexa and Zyprexa Zydis prescribing information. Eli Lilly and Company. April 2021.
4	Seroquel prescribing information. AstraZeneca Pharmaceuticals LP. January 2022.
5	Geodon prescribing information. Roerig – Pfizer Inc. February 2022.
6	Abilify prescribing information. Otsuka America Pharmaceutical, Inc. November 2022.
7	Invega prescribing information. Janssen, Pharmaceuticals, Inc. March 2022.
8	Seroquel XR prescribing information. AstraZeneca Pharmaceuticals LP. January 2022.
9	Saphris prescribing information. Allergan USA, Inc. February 2017.
10	Fanapt prescribing information. Vanda Pharmaceuticals Inc. February 2017.
11	Latuda prescribing information. Sunovion Pharmaceuticals Inc. December 2019.
12	Clozapine ODT prescribing information. Teva Pharmaceuticals USA, Inc. April 2023.
13	Versacloz prescribing information. TruPharma, LLC. March 2023.
14	Rexulti prescribing information. Otsuka Pharmaceutical Co., Ltd. May 2023.
15	Vraylar prescribing information. Allergan USA, Inc. December 2022.
16	Patel KR, Cherian J, Gohil K, Atkinson D. Schizophrenia: overview and treatment options. P T. 2014;39(9):638-645.
17	Keepers, George A. MD., et al. Treatment of Patients with Schizophrenia. American Psychiatric Association. Third edition. September 2020. Accessed at: https://psychiatryonline.org/doi/pdf/10.1176/appi.books.9780890424841.
18	Hirschfield, Robert M. Guideline Watch: Practice Guideline for the Treatment of Patients with Bipolar Disorder. American Psychiatric Association. Second edition. November 2005. Available at: https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/bipolar-watch.pdf .
19	Yatham, LN, Kennedy SH et. Al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disorders. 2018; 20:97-170. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947163/pdf/BDI-20-97.pdf.
20	Simon, Gregory, MD, MPH, et al. Unipolar Major Depression in Adults: Choosing Initial Treatment. UpToDate. Last updated November 2017.
21	Glenberg, Alan MD., et al. Practice guideline for the treatment of patients with Major Depressive Disorder. American Psychiatric Association. Third edition. October 2010. Available at: https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf.
22	Volkmar F, Siegel M, Woodbury-Smith M, et al. Practice parameter for the assessment and treatment of children and adolescents with autism spectrum disorder. J Am Acad Child Adolesc Psych. 2014;53(2):237–257.
23	AHRQ Draft Report: Therapies for Children with Autism Spectrum Disorder. May 2020. Available at: https://effectivehealthcare.ahrq.gov/products/autism-update/consumer.
24	Rabins, Peter, MD, MPH, et al. Practice Guideline for the Treatment of Patients with Alzheimer's Disease and Other Dementias. Second Edition. American Psychiatric Association. Available at: https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/alzheimers.pdf.
25	Reus, Victor, MD, et al. Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients with Dementia. First Edition. May 2016. American Psychiatric Association. Available at: https://psychiatryonline.org/doi/book/10.1176/appi.books.9780890426807.

Number	Reference
26	Serajee F, Huq A. Advances in Tourette syndrome: diagnoses and treatment. Pediatr Clin N Am 2015;62:687–701.
27	Murphy T. K., et. al. Practice parameters for the assessment and treatment of children and adolescents with tic disorders. Journal of the American Academy of Child & Adolescent Psychiatry. Dec 2013; Vol 52, #12: 1341-1359.
	Pringsheim, Tamara, MD., et al. Practice Guideline Recommendations Summary: Treatment of Tics in People with Tourettes Syndrome and Chronic Tic Disorders. May 2019. Available at:https://n.neurology.org/content/92/19/896.
29	Padala, P.R., Oadri, S.F., & Madaan, V. (2005). Aripiprazole for the Treatment of Tourette's Disorder. Primary Care Companion to the Journal of Clinical Psychiatry, 7(6), 296–299. https://doi.org/10.4088/pcc.v07n0605.
30	Abilify Mycite prescribing information. Otsuka America Pharmaceutical, Inc. November 2022.
31	Secuado prescribing information. Hisamitsu Pharmaceutical Co, Inc. December 2023.
32	Caplyta prescribing information. Intra-Cellular Therapies, Inc. June 2023.
33	Lybalvi prescribing information. Alkermes, Inc. September 2023.

POLICY AGENT SUMMARY STEP THERAPY

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Targeted MSC	Availabl e MSC	Final Age Limit	Preferred Status
	aripiprazole oral solution	1 MG/ML	M;N;O	Y		
	aripiprazole orally disintegrating tab	10 MG ; 15 MG	M;N;O	Y		
	risperidone orally disintegrating tab	0.25 MG; 0.5 MG; 1 MG; 2 MG; 3 MG; 4 MG	M;N;O	N;Y		
Abilify	aripiprazole tab	10 ; 10 MG; 15 MG; 2 ; 2 MG; 20 ; 20 MG; 30 MG; 5 MG	M;N;O	O; Y		
Abilify mycite	aripiprazole tab	10 MG ; 15 MG ; 2 MG ; 20 MG ; 30 MG ; 5 MG	M;N;O	N		
Abilify mycite maintenanc ; Abilify mycite starter ki	aripiprazole tab	10 MG ; 15 MG ; 2 MG ; 20 MG ; 30 MG ; 5 MG	M;N;O	N		
Caplyta	lumateperone tosylate cap	10.5 MG ; 21 MG ; 42 MG	M;N;O	N		
Clozaril ; Versacloz	clozapine orally disintegrating tab ; clozapine susp ; clozapine tab	100 MG; 12.5 MG; 150 MG; 200 MG; 25 MG; 50 MG; 50 MG/ML	M;N;O	N;O;Y		
Fanapt ; Fanapt titration pack	iloperidone tab	1 & 2 & 4 & 6 MG; 1 MG; 10 MG; 12 MG; 2 MG; 4 MG; 6 MG; 8 MG	M;N;O	N		
Geodon	ziprasidone hcl cap	20 MG ; 40 MG ; 60 MG ; 80 MG	M;N;O	O ; Y		
Invega	paliperidone tab er	1.5 MG ; 3 MG ; 6 MG ; 9 MG	M;N;O	O ; Y		
Latuda	lurasidone hcl tab	120 MG ; 20 MG ; 40 MG ; 60 MG ; 80 MG	M;N;O	O ; Y		

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Targeted MSC	Availabl e MSC	Final Age Limit	Preferred Status
Lybalvi	olanzapine-samidorphan l-malate tab	10-10 MG ; 15- 10 MG ; 20-10 MG ; 5-10 MG	M;N;O	N		
Rexulti	brexpiprazole tab	0.25 MG; 0.5 MG; 1 MG; 2 MG; 3 MG; 4 MG	M;N;O	N		
Risperdal	risperidone soln	1 MG/ML	M;N;O	O ; Y		
Risperdal	risperidone tab	0.25 MG; 0.5 MG; 1 MG; 2 MG; 3 MG; 4 MG	M;N;O	O;Y		
Saphris ; Secuado	asenapine maleate sl tab ; asenapine td patch	10 MG; 2.5 MG; 3.8 MG/24HR; 5 MG; 5.7 MG/24HR; 7.6 MG/24HR	M;N;O	N;O;Y		
Seroquel	quetiapine fumarate tab	100 MG; 150 MG; 200 MG; 25 MG; 300 MG; 400; 400 MG; 50 MG	M;N;O	N;O;Y		
Seroquel ; Seroquel xr	quetiapine fumarate tab ; quetiapine fumarate tab er	100 MG; 150 MG; 200 MG; 25 MG; 300 MG; 400; 400 MG; 50 MG	M;N;O	N;O;Y		
Seroquel xr	quetiapine fumarate tab er	150 MG; 200 MG; 300 MG; 400 MG; 50 MG	M;N;O	O;Y		
Vraylar	cariprazine hcl cap ; cariprazine hcl cap therapy pack	1.5 & 3 MG; 1.5 MG; 3 MG; 4.5 MG; 6 MG	M;N;O	N		
Zyprexa	olanzapine tab	10 MG; 15 MG; 2.5 MG; 20 MG; 5 MG; 7.5 MG	M;N;O	O;Y		
Zyprexa zydis	olanzapine orally disintegrating tab	10 MG ; 15 MG ; 20 MG ; 5 MG	M;N;O	O;Y		

POLICY AGENT SUMMARY QUANTITY LIMIT

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strengt h	QL Amount	Dose Form	Day Supply	Duratio n	•	Allowed Exceptions	Targete d NDCs When Exclusi ons Exist
	Aripiprazole Oral Solution 1 MG/ML	1 MG/ML	900	mLs	30	DAYS			
	aripiprazole orally disintegrating tab	10 MG ; 15 MG	60	Tablets	30	DAYS			
	Aripiprazole Orally Disintegrating Tab 10 MG	10 MG	60	Tablets	30	DAYS			
	Aripiprazole Orally Disintegrating Tab 15 MG	15 MG	60	Tablets	30	DAYS			

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strengt h	QL Amount	Dose Form	Day Supply	Duratio n	Addtl QL Info	Allowed Exceptions	Targete d NDCs When Exclusi ons Exist
	Clozapine Orally Disintegrating Tab 100 MG	100 MG	90	Tablets	30	DAYS			
	Clozapine Orally Disintegrating Tab 12.5 MG	12.5 MG	90	Tablets	30	DAYS			
	Clozapine Orally Disintegrating Tab 150 MG	150 MG	180	Tablets	30	DAYS			
	Clozapine Orally Disintegrating Tab 200 MG	200 MG	120	Tablets	30	DAYS			
	Clozapine Orally Disintegrating Tab 25 MG	25 MG	270	Tablets	30	DAYS			
	Quetiapine Fumarate Tab	150 MG	30	Tablets	30	DAYS			
	Risperidone Orally Disintegrating Tab 0.25 MG	0.25 MG	60	Tablets	30	DAYS			
	Risperidone Orally Disintegrating Tab 0.5 MG	0.5 MG	60	Tablets	30	DAYS			
	Risperidone Orally Disintegrating Tab 1 MG	1 MG	60	Tablets	30	DAYS			
	Risperidone Orally Disintegrating Tab 2 MG	2 MG	60	Tablets	30	DAYS			
	Risperidone Orally Disintegrating Tab 3 MG	3 MG	60	Tablets	30	DAYS			
	Risperidone Orally Disintegrating Tab 4 MG	4 MG	120	Tablets	30	DAYS			
	Risperidone Tab 0.25	0.25 MG	60	Tablets	30	DAYS			
Abilify	Aripiprazole Tab 10 MG	10 ; 10 MG	30	Tablets	30	DAYS			
Abilify	Aripiprazole Tab 15 MG	15 MG	30	Tablets	30	DAYS			
Abilify	Aripiprazole Tab 2 MG	2 ; 2 MG	30	Tablets	30	DAYS			
Abilify	Aripiprazole Tab 20 MG	20 ; 20 MG	30	Tablets	30	DAYS			
Abilify	Aripiprazole Tab 30 MG	30 MG	30	Tablets	30	DAYS			
Abilify	Aripiprazole Tab 5 MG	5 MG	30	Tablets	30	DAYS			
Abilify mycite maintenanc	Aripiprazole Tab	2 MG	30	Tablets	30	DAYS			
Abilify mycite maintenanc	Aripiprazole Tab	5 MG	30	Tablets	30	DAYS			
Abilify mycite maintenanc	Aripiprazole Tab	10 MG	30	Tablets	30	DAYS			
Abilify mycite maintenanc	Aripiprazole Tab	15 MG	30	Tablets	30	DAYS			
Abilify mycite maintenanc	Aripiprazole Tab	20 MG	30	Tablets	30	DAYS			
Abilify mycite maintenanc	Aripiprazole Tab	30 MG	30	Tablets	30	DAYS			

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strengt h	QL Amount	Dose Form	Day Supply	Duratio n	Addtl QL Info	Allowed Exceptions	Targete d NDCs When Exclusi ons Exist
Abilify mycite starter ki	Aripiprazole Tab	2 MG	30	Tablets	30	DAYS			
Abilify mycite starter	Aripiprazole Tab	5 MG	30	Tablets	30	DAYS			
Abilify mycite starter ki	Aripiprazole Tab	10 MG	30	Tablets	30	DAYS			
Abilify mycite starter	Aripiprazole Tab	15 MG	30	Tablets	30	DAYS			
Abilify mycite starter ki	Aripiprazole Tab	20 MG	30	Tablets	30	DAYS			
Abilify mycite starter ki	Aripiprazole Tab	30 MG	30	Tablets	30	DAYS			
Caplyta	Lumateperone Tosylate Cap	10.5 MG	30	Capsule s	30	DAYS			
Caplyta	Lumateperone Tosylate Cap	21 MG	30	Capsule s	30	DAYS			
Caplyta	lumateperone tosylate cap	10.5 MG ; 21 MG ; 42 MG	30	Capsule s	30	DAYS			
Caplyta	Lumateperone Tosylate Cap 42 MG	42 MG	30	Capsule s	30	DAYS			
Clozaril	Clozapine Tab 100 MG	100 MG	270	Tablets	30	DAYS			
Clozaril	Clozapine Tab 200 MG	200 MG	120	Tablets	30	DAYS			
Clozaril	Clozapine Tab 25 MG	25 MG	90	Tablets	30	DAYS			
Clozaril	Clozapine Tab 50 MG	50 MG	90	Tablets	30	DAYS			
Fanapt	iloperidone tab	1 MG; 10 MG; 12 MG; 2 MG; 4 MG; 6 MG; 8 MG	60	Tablets	30	DAYS			
Fanapt	Iloperidone Tab 1 MG	1 MG	60	Tablets	30	DAYS			
Fanapt	Iloperidone Tab 10 MG	10 MG	60	Tablets	30	DAYS			
Fanapt	Iloperidone Tab 12 MG	12 MG	60	Tablets	30	DAYS			
Fanapt	Iloperidone Tab 2 MG	2 MG	60	Tablets	30	DAYS			
Fanapt	Iloperidone Tab 4 MG	4 MG	60	Tablets	30	DAYS			
Fanapt	Iloperidone Tab 6 MG	6 MG	60	Tablets	30	DAYS			
Fanapt	Iloperidone Tab 8 MG	8 MG	60	Tablets	30	DAYS			
Fanapt titration pack	Iloperidone Tab 1 MG & 2 MG & 4 MG & 6 MG Titration Pak	1 & 2 & 4 & 6 MG	1	Pack	180	DAYS			
Geodon	ziprasidone hcl cap	20 MG; 40 MG; 60 MG; 80 MG	60	Tablets	30	DAYS			
Geodon	Ziprasidone HCl Cap 20 MG	20 MG	60	Capsule s	30	DAYS			
Geodon	Ziprasidone HCl Cap 40 MG	40 MG	60	Capsule s	30	DAYS			
Geodon	Ziprasidone HCl Cap 60 MG	60 MG	60	Capsule s	30	DAYS			

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strengt h	QL Amount	Dose Form	Day Supply	Duratio n	Addtl QL Info	Allowed Exceptions	Targete d NDCs When Exclusi ons Exist
Geodon	Ziprasidone HCl Cap 80 MG	80 MG	60	Capsule s	30	DAYS			
Invega	Paliperidone Tab ER 24HR 1.5 MG	1.5 MG	30	Tablets	30	DAYS			
Invega	Paliperidone Tab ER 24HR 3 MG	3 MG	30	Tablets	30	DAYS			
Invega	Paliperidone Tab ER 24HR 6 MG	6 MG	60	Tablets	30	DAYS			
Invega	Paliperidone Tab ER 24HR 9 MG	9 MG	30	Tablets	30	DAYS			
Latuda	Lurasidone HCl Tab 120 MG	120 MG	30	Tablets	30	DAYS			
Latuda	Lurasidone HCl Tab 20 MG	20 MG	30	Tablets	30	DAYS			
Latuda	Lurasidone HCl Tab 40 MG	40 MG	30	Tablets	30	DAYS			
Latuda	Lurasidone HCl Tab	60 MG	30	Tablets	30	DAYS			
Latuda	Lurasidone HCl Tab 80 MG	80 MG	60	Tablets	30	DAYS			
Lybalvi	Olanzapine- Samidorphan L- Malate Tab	5-10 MG	30	Tablets	30	DAYS			
Lybalvi	Olanzapine- Samidorphan L- Malate Tab	10-10 MG	30	Tablets	30	DAYS			
Lybalvi	Olanzapine- Samidorphan L- Malate Tab	15-10 MG	30	Tablets	30	DAYS			
Lybalvi	Olanzapine- Samidorphan L- Malate Tab	20-10 MG	30	Tablets	30	DAYS			
Rexulti	brexpiprazole tab	0.25 MG ; 0.5 MG ; 1 MG; 2 MG; 3 MG; 4 MG		Tablets	30	DAYS			
Rexulti	Brexpiprazole Tab 0.25 MG	0.25 MG	30	Tablets	30	DAYS			
Rexulti	Brexpiprazole Tab 0.5 MG	0.5 MG	30	Tablets	30	DAYS			
Rexulti	Brexpiprazole Tab 1 MG	1 MG	30	Tablets	30	DAYS			
Rexulti	Brexpiprazole Tab 2 MG	2 MG	30	Tablets	30	DAYS			
Rexulti	Brexpiprazole Tab 3 MG	3 MG	30	Tablets	30	DAYS			
Rexulti	Brexpiprazole Tab 4	4 MG	30	Tablets	30	DAYS			
Risperdal	Risperidone Soln 1 MG/ML	1 MG/ML	480	mLs	30	DAYS			
Risperdal	Risperidone Tab 0.5	0.5 MG	60	Tablets	30	DAYS			
Risperdal	Risperidone Tab 1 MG	1 MG	60	Tablets	30	DAYS			
Risperdal	Risperidone Tab 2 MG	2 MG	60	Tablets	30	DAYS			
Risperdal	Risperidone Tab 3	3 MG	60	Tablets	30	DAYS			

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strengt h	QL Amount	Dose Form	Day Supply	Duratio n	Addtl QL Info	Allowed Exceptions	Targete d NDCs When Exclusi ons Exist
Risperdal	Risperidone Tab 4	4 MG	120	Tablets	30	DAYS			
Saphris	asenapine maleate sl tab	10 MG ; 2.5 MG ; 5 MG	60	Tablets	30	DAYS			
Saphris	Asenapine Maleate SL Tab 10 MG (Base Equiv)	10 MG	60	Tablets	30	DAYS			
Saphris	Asenapine Maleate SL Tab 2.5 MG (Base Equiv)	2.5 MG	60	Tablets	30	DAYS			
Saphris	Asenapine Maleate SL Tab 5 MG (Base Equiv)	5 MG	60	Tablets	30	DAYS			
Secuado	asenapine td patch	3.8 MG/24H R; 5.7 MG/24H R; 7.6 MG/24H R	30	Patches	30	DAYS			
Secuado	Asenapine TD Patch 24 HR 3.8 MG/24HR	3.8 MG/24H R	30	Patches	30	DAYS			
Secuado	Asenapine TD Patch 24 HR 5.7 MG/24HR	5.7 MG/24H R	30	Patches	30	DAYS			
Secuado	Asenapine TD Patch 24 HR 7.6 MG/24HR	7.6 MG/24H R	30	Patches	30	DAYS			
Seroquel	Quetiapine Fumarate Tab 100 MG	100 MG	90	Tablets	30	DAYS			
Seroquel	Quetiapine Fumarate Tab 200 MG	200 MG	90	Tablets	30	DAYS			
Seroquel	Quetiapine Fumarate Tab 25 MG	25 MG	90	Tablets	30	DAYS			
Seroquel	Quetiapine Fumarate Tab 300 MG	300 MG	60	Tablets	30	DAYS			
Seroquel	Quetiapine Fumarate Tab 400 MG	400 ; 400 MG	60	Tablets	30	DAYS			
Seroquel	Quetiapine Fumarate Tab 50 MG	50 MG	90	Tablets	30	DAYS			
Seroquel xr	quetiapine fumarate tab er	150 MG ; 200 MG ; 300 MG ; 400 MG ; 50 MG	60	Tablets	30	DAYS			
Seroquel xr	Quetiapine Fumarate Tab ER 24HR 150 MG	150 MG	30	Tablets	30	DAYS			
Seroquel xr	Quetiapine Fumarate Tab ER 24HR 200 MG	200 MG	30	Tablets	30	DAYS			
Seroquel xr	Quetiapine Fumarate Tab ER 24HR 300 MG	300 MG	60	Tablets	30	DAYS			
Seroquel xr	Quetiapine Fumarate Tab ER 24HR 400 MG	400 MG	60	Tablets	30	DAYS			
Seroquel xr	Quetiapine Fumarate Tab ER 24HR 50 MG	50 MG	60	Tablets	30	DAYS			
Versacloz	clozapine susp	50 MG/ML	540	mLs	30	DAYS			
Versacloz	Clozapine Susp 50 MG/ML	50 MG/ML	540	mLs	30	DAYS			

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strengt h	QL Amount	Dose Form	Day Supply	Duratio n	Addtl QL Info	Allowed Exceptions	Targete d NDCs When Exclusi ons Exist
Vraylar	cariprazine hcl cap	1.5 MG; 3 MG; 4.5 MG; 6 MG	30	Capsule s	30	DAYS			
Vraylar	Cariprazine HCl Cap 1.5 MG (Base Equivalent)	1.5 MG	30	Capsule s	30	DAYS			
Vraylar	Cariprazine HCl Cap 3 MG (Base Equivalent)	3 MG	30	Capsule s	30	DAYS			
Vraylar	Cariprazine HCl Cap 4.5 MG (Base Equivalent)	4.5 MG	30	Capsule s	30	DAYS			
Vraylar	Cariprazine HCl Cap 6 MG (Base Equivalent)	6 MG	30	Capsule s	30	DAYS			
Vraylar	Cariprazine HCl Cap Therapy Pack 1.5 MG (1) & 3 MG (6)	1.5 & 3 MG	7	Capsule s	180	DAYS			
Zyprexa	olanzapine tab	10 MG; 15 MG; 2.5 MG; 20; 20 MG; 5 MG; 7.5 MG	30	Tablets	30	DAYS			
Zyprexa	Olanzapine Tab 10 MG	10 MG	30	Tablets	30	DAYS			
Zyprexa	Olanzapine Tab 15 MG	15 MG	30	Tablets	30	DAYS			
Zyprexa	Olanzapine Tab 2.5 MG	2.5 MG	30	Tablets	30	DAYS			
Zyprexa	Olanzapine Tab 20 MG	20 ; 20 MG	30	Tablets	30	DAYS			
Zyprexa	Olanzapine Tab 5 MG	5 MG	30	Tablets	30	DAYS			
Zyprexa	Olanzapine Tab 7.5 MG	7.5 MG	30	Tablets	30	DAY			
Zyprexa zydis	olanzapine orally disintegrating tab	10 MG; 15 MG; 20 MG; 5 MG	30	Tablets	30	DAYS			
Zyprexa zydis	Olanzapine Orally Disintegrating Tab 10 MG	10 MG	30	Tablets	30	DAYS			
Zyprexa zydis	Olanzapine Orally Disintegrating Tab 15 MG	15 MG	30	Tablets	30	DAYS			
Zyprexa zydis	Olanzapine Orally Disintegrating Tab 20 MG	20 MG	30	Tablets	30	DAYS			
Zyprexa zydis	Olanzapine Orally Disintegrating Tab 5 MG	5 MG	30	Tablets	30	DAYS			

CLIENT SUMMARY - STEP THERAPY

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
	aripiprazole oral solution		FlexRx Open ; FocusRx ; GenRx Open ; Health Insurance

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
			Marketplace/BasicRx; KeyRx
	aripiprazole orally disintegrating tab	10 MG ; 15 MG	FlexRx Open ; FocusRx ; GenRx Open ; Health Insurance Marketplace/BasicRx ; KeyRx
	risperidone orally disintegrating tab	0.25 MG; 0.5 MG; 1 MG; 2 MG; 3 MG; 4 MG	FlexRx Open ; FocusRx ; GenRx Open ; Health Insurance Marketplace/BasicRx ; KeyRx
Abilify	aripiprazole tab	10 ; 10 MG; 15 MG; 2 ; 2 MG; 20 ; 20 MG; 30 MG; 5 MG	FlexRx Open ; FocusRx ; GenRx Open ; Health Insurance Marketplace/BasicRx ; KeyRx
Abilify mycite maintenanc ; Abilify mycite starter ki	aripiprazole tab	10 MG; 15 MG; 2 MG; 20 MG; 30 MG; 5 MG	FlexRx Open ; FocusRx ; GenRx Open ; Health Insurance Marketplace/BasicRx ; KeyRx
Caplyta	lumateperone tosylate cap	10.5 MG ; 21 MG ; 42 MG	FlexRx Open ; FocusRx ; GenRx Open ; Health Insurance Marketplace/BasicRx ; KeyRx
Clozaril ; Versacloz	clozapine orally disintegrating tab ; clozapine susp ; clozapine tab	100 MG; 12.5 MG; 150 MG; 200 MG; 25 MG; 50 MG; 50 MG/ML	FlexRx Open ; FocusRx ; GenRx Open ; Health Insurance Marketplace/BasicRx ; KeyRx
Fanapt ; Fanapt titration pack	iloperidone tab	1 & 2 & 4 & 6 MG; 1 MG; 10 MG; 12 MG; 2 MG; 4 MG; 6 MG; 8 MG	FlexRx Open ; FocusRx ; GenRx Open ; Health Insurance Marketplace/BasicRx ; KeyRx
Geodon	ziprasidone hcl cap	20 MG; 40 MG; 60 MG; 80 MG	FlexRx Open ; FocusRx ; GenRx Open ; Health Insurance Marketplace/BasicRx ; KeyRx
Invega	paliperidone tab er	1.5 MG; 3 MG; 6 MG; 9 MG	FlexRx Open ; FocusRx ; GenRx Open ; Health Insurance Marketplace/BasicRx ; KeyRx
Latuda	lurasidone hcl tab	120 MG; 20 MG; 40 MG; 60 MG; 80 MG	FlexRx Open ; FocusRx ; GenRx Open ; Health Insurance Marketplace/BasicRx ; KeyRx
Lybalvi	olanzapine-samidorphan l-malate tab	10-10 MG ; 15-10 MG ; 20-10 MG ; 5-10 MG	FlexRx Open ; FocusRx ; GenRx Open ; Health Insurance Marketplace/BasicRx ; KeyRx
Rexulti	brexpiprazole tab	0.25 MG; 0.5 MG; 1 MG; 2 MG; 3 MG; 4 MG	FlexRx Open ; FocusRx ; GenRx Open ; Health Insurance Marketplace/BasicRx ; KeyRx
Risperdal	risperidone soln	1 MG/ML	FlexRx Open ; FocusRx ; GenRx Open ; Health Insurance Marketplace/BasicRx ; KeyRx
Risperdal	risperidone tab	0.25 MG; 0.5 MG; 1 MG; 2 MG; 3 MG; 4 MG	FlexRx Open ; FocusRx ; GenRx Open ; Health Insurance Marketplace/BasicRx ; KeyRx

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
Saphris ; Secuado	asenapine maleate sl tab ; asenapine td patch	10 MG; 2.5 MG; 3.8 MG/24HR; 5 MG; 5.7 MG/24HR; 7.6 MG/24HR	FlexRx Open ; FocusRx ; GenRx Open ; Health Insurance Marketplace/BasicRx ; KeyRx
Seroquel	quetiapine fumarate tab	100 MG; 150 MG; 200 MG; 25 MG; 300 MG; 400; 400 MG; 50 MG	FlexRx Open ; FocusRx ; GenRx Open ; Health Insurance Marketplace/BasicRx ; KeyRx
Seroquel xr	quetiapine fumarate tab er	150 MG; 200 MG; 300 MG; 400 MG; 50 MG	FlexRx Open ; FocusRx ; GenRx Open ; Health Insurance Marketplace/BasicRx ; KeyRx
Vraylar	cariprazine hcl cap ; cariprazine hcl cap therapy pack	1.5 & 3 MG ; 1.5 MG ; 3 MG ; 4.5 MG ; 6 MG	FlexRx Open ; FocusRx ; GenRx Open ; Health Insurance Marketplace/BasicRx ; KeyRx
Zyprexa	olanzapine tab	10 MG; 15 MG; 2.5 MG; 20; 20 MG; 5 MG; 7.5 MG	FlexRx Open ; FocusRx ; GenRx Open ; Health Insurance Marketplace/BasicRx ; KeyRx
Zyprexa zydis	olanzapine orally disintegrating tab	10 MG; 15 MG; 20 MG; 5 MG	FlexRx Open ; FocusRx ; GenRx Open ; Health Insurance Marketplace/BasicRx ; KeyRx

CLIENT SUMMARY - QUANTITY LIMITS

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
	Aripiprazole Oral Solution 1 MG/ML	1 MG/ML	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
	aripiprazole orally disintegrating tab	10 MG ; 15 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
	Aripiprazole Orally Disintegrating Tab 10 MG	10 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
	Aripiprazole Orally Disintegrating Tab 15 MG	15 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
	Clozapine Orally Disintegrating Tab 100 MG	100 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
	Clozapine Orally Disintegrating Tab 12.5 MG	12.5 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
	Clozapine Orally Disintegrating Tab 150 MG	150 MG	FlexRx Closed ; FlexRx Open ; FocusRx ; GenRx

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
			Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
	Clozapine Orally Disintegrating Tab 200 MG	200 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
	Clozapine Orally Disintegrating Tab 25 MG	25 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
	Quetiapine Fumarate Tab	150 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
	Risperidone Orally Disintegrating Tab 0.25 MG	0.25 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
	Risperidone Orally Disintegrating Tab 0.5 MG	0.5 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
	Risperidone Orally Disintegrating Tab 1 MG	1 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
	Risperidone Orally Disintegrating Tab 2 MG	2 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
	Risperidone Orally Disintegrating Tab 3 MG	3 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
	Risperidone Orally Disintegrating Tab 4 MG	4 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
	Risperidone Tab 0.25 MG	0.25 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Abilify	Aripiprazole Tab 10 MG	10 ; 10 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Abilify	Aripiprazole Tab 15 MG	15 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
			Marketplace/BasicRx; KeyRx
Abilify	Aripiprazole Tab 2 MG	2 ; 2 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Abilify	Aripiprazole Tab 20 MG	20 ; 20 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Abilify	Aripiprazole Tab 30 MG	30 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Abilify	Aripiprazole Tab 5 MG	5 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Abilify mycite maintenanc	Aripiprazole Tab	5 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Abilify mycite maintenanc	Aripiprazole Tab	10 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Abilify mycite maintenanc	Aripiprazole Tab	20 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Abilify mycite maintenanc	Aripiprazole Tab	30 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Abilify mycite maintenanc	Aripiprazole Tab	2 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Abilify mycite maintenanc	Aripiprazole Tab	15 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Abilify mycite starter ki	Aripiprazole Tab	30 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Abilify mycite starter ki	Aripiprazole Tab	5 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
Abilify mycite starter ki	Aripiprazole Tab	20 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Abilify mycite starter ki	Aripiprazole Tab	15 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Abilify mycite starter ki	Aripiprazole Tab	2 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Abilify mycite starter ki	Aripiprazole Tab	10 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Caplyta	Lumateperone Tosylate Cap	21 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Caplyta	Lumateperone Tosylate Cap	10.5 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Caplyta	lumateperone tosylate cap	10.5 MG ; 21 MG ; 42 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Caplyta	Lumateperone Tosylate Cap 42 MG	42 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Clozaril	Clozapine Tab 100 MG	100 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Clozaril	Clozapine Tab 200 MG	200 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Clozaril	Clozapine Tab 25 MG	25 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Clozaril	Clozapine Tab 50 MG	50 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Fanapt	iloperidone tab	1 MG; 10 MG; 12 MG; 2 MG; 4 MG; 6 MG; 8 MG	FlexRx Closed ; FlexRx Open ; FocusRx ; GenRx

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
			Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Fanapt	Iloperidone Tab 1 MG	1 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Fanapt	Iloperidone Tab 10 MG	10 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Fanapt	Iloperidone Tab 12 MG	12 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Fanapt	Iloperidone Tab 2 MG	2 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Fanapt	Iloperidone Tab 4 MG	4 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Fanapt	Iloperidone Tab 6 MG	6 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Fanapt	Iloperidone Tab 8 MG	8 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Fanapt titration pack	Iloperidone Tab 1 MG & 2 MG & 4 MG & 6 MG Titration Pak	1 & 2 & 4 & 6 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Geodon	ziprasidone hcl cap	20 MG; 40 MG; 60 MG; 80 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Geodon	Ziprasidone HCl Cap 20 MG	20 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Geodon	Ziprasidone HCl Cap 40 MG	40 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Geodon	Ziprasidone HCl Cap 60 MG	60 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
			Marketplace/BasicRx; KeyRx
Geodon	Ziprasidone HCl Cap 80 MG	80 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Invega	Paliperidone Tab ER 24HR 1.5 MG	1.5 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Invega	Paliperidone Tab ER 24HR 3 MG	3 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Invega	Paliperidone Tab ER 24HR 6 MG	6 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Invega	Paliperidone Tab ER 24HR 9 MG	9 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Latuda	Lurasidone HCl Tab 120 MG	120 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Latuda	Lurasidone HCl Tab 20 MG	20 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Latuda	Lurasidone HCl Tab 40 MG	40 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Latuda	Lurasidone HCl Tab 60 MG	60 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Latuda	Lurasidone HCl Tab 80 MG	80 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Lybalvi	Olanzapine-Samidorphan L-Malate Tab	10-10 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Lybalvi	Olanzapine-Samidorphan L-Malate Tab	20-10 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
Lybalvi	Olanzapine-Samidorphan L-Malate Tab	5-10 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Lybalvi	Olanzapine-Samidorphan L-Malate Tab	15-10 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Rexulti	brexpiprazole tab	0.25 MG; 0.5 MG; 1 MG; 2 MG; 3 MG; 4 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Rexulti	Brexpiprazole Tab 0.25 MG	0.25 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Rexulti	Brexpiprazole Tab 0.5 MG	0.5 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Rexulti	Brexpiprazole Tab 1 MG	1 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Rexulti	Brexpiprazole Tab 2 MG	2 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Rexulti	Brexpiprazole Tab 3 MG	3 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Rexulti	Brexpiprazole Tab 4 MG	4 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Risperdal	Risperidone Soln 1 MG/ML	1 MG/ML	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Risperdal	Risperidone Tab 0.5 MG	0.5 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Risperdal	Risperidone Tab 1 MG	1 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Risperdal	Risperidone Tab 2 MG	2 MG	FlexRx Closed ; FlexRx Open ; FocusRx ; GenRx

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
			Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Risperdal	Risperidone Tab 3 MG	3 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Risperdal	Risperidone Tab 4 MG	4 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Saphris	asenapine maleate sl tab	10 MG; 2.5 MG; 5 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Saphris	Asenapine Maleate SL Tab 10 MG (Base Equiv)	10 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Saphris	Asenapine Maleate SL Tab 2.5 MG (Base Equiv)	2.5 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Saphris	Asenapine Maleate SL Tab 5 MG (Base Equiv)	5 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Secuado	asenapine td patch	3.8 MG/24HR ; 5.7 MG/24HR ; 7.6 MG/24HR	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Secuado	Asenapine TD Patch 24 HR 3.8 MG/24HR	3.8 MG/24HR	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Secuado	Asenapine TD Patch 24 HR 5.7 MG/24HR	5.7 MG/24HR	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Secuado	Asenapine TD Patch 24 HR 7.6 MG/24HR	7.6 MG/24HR	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Seroquel	Quetiapine Fumarate Tab 100 MG	100 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Seroquel	Quetiapine Fumarate Tab 200 MG	200 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
			Marketplace/BasicRx; KeyRx
Seroquel	Quetiapine Fumarate Tab 25 MG	25 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Seroquel	Quetiapine Fumarate Tab 300 MG	300 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Seroquel	Quetiapine Fumarate Tab 400 MG	400 ; 400 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Seroquel	Quetiapine Fumarate Tab 50 MG	50 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Seroquel xr	quetiapine fumarate tab er	150 MG; 200 MG; 300 MG; 400 MG; 50 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Seroquel xr	Quetiapine Fumarate Tab ER 24HR 150 MG	150 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Seroquel xr	Quetiapine Fumarate Tab ER 24HR 200 MG	200 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Seroquel xr	Quetiapine Fumarate Tab ER 24HR 300 MG	300 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Seroquel xr	Quetiapine Fumarate Tab ER 24HR 400 MG	400 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Seroquel xr	Quetiapine Fumarate Tab ER 24HR 50 MG	50 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Versacloz	clozapine susp	50 MG/ML	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Versacloz	Clozapine Susp 50 MG/ML	50 MG/ML	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
Vraylar	cariprazine hcl cap	1.5 MG; 3 MG; 4.5 MG; 6 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Vraylar	Cariprazine HCl Cap 1.5 MG (Base Equivalent)	1.5 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Vraylar	Cariprazine HCl Cap 3 MG (Base Equivalent)	3 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Vraylar	Cariprazine HCl Cap 4.5 MG (Base Equivalent)	4.5 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Vraylar	Cariprazine HCl Cap 6 MG (Base Equivalent)	6 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Vraylar	Cariprazine HCl Cap Therapy Pack 1.5 MG (1) & 3 MG (6)	1.5 & 3 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Zyprexa	olanzapine tab	10 MG; 15 MG; 2.5 MG; 20; 20 MG; 5 MG; 7.5 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Zyprexa	Olanzapine Tab 10 MG	10 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Zyprexa	Olanzapine Tab 15 MG	15 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Zyprexa	Olanzapine Tab 2.5 MG	2.5 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Zyprexa	Olanzapine Tab 20 MG	20 ; 20 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Zyprexa	Olanzapine Tab 5 MG	5 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Zyprexa	Olanzapine Tab 7.5 MG	7.5 MG	FlexRx Closed ; FlexRx Open ; FocusRx ; GenRx

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
			Closed ; GenRx Open ; Health Insurance Marketplace/BasicRx ; KeyRx
Zyprexa zydis	olanzapine orally disintegrating tab	10 MG; 15 MG; 20 MG; 5 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Zyprexa zydis	Olanzapine Orally Disintegrating Tab 10 MG	10 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Zyprexa zydis	Olanzapine Orally Disintegrating Tab 15 MG	15 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Zyprexa zydis	Olanzapine Orally Disintegrating Tab 20 MG	20 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx
Zyprexa zydis	Olanzapine Orally Disintegrating Tab 5 MG	5 MG	FlexRx Closed; FlexRx Open; FocusRx; GenRx Closed; GenRx Open; Health Insurance Marketplace/BasicRx; KeyRx

STEP THERAPY CLINICAL CRITERIA FOR APPROVAL

Clinical Criteria for Approval		
Target Agent(s)	Prerequisite Agents	
	Any generic atypical antipsychotic	
Abilify (aripiprazole)*	Any generic antidepressant (i.e., SSRI, SNRI, bupropion, mirtazapine, or vilazodone)	
	haloperidol or pimozide	
Abilify Mycite (aripiprazole) Rexulti (brexpiprazole) Seroquel XR (quetiapine)* Vraylar (cariprazine)	Any generic atypical antipsychotic Any generic antidepressant (i.e., SSRI, SNRI, bupropion, mirtazapine, or vilazodone)	
Zyprexa (olanzapine)*	Any generic atypical antipsychotic	
Zyprexa Zydis (olanzapine)*	Generic fluoxetine	
Caplyta (lumateperone) Clozapine ODT Clozaril (clozapine)* Fanapt (iloperidone) Geodon (ziprasidone)* Invega (paliperidone)* Latuda (lurasidone)* Lybalvi (olanzapine/samidorphan)	Any generic atypical antipsychotic	

Module	Clinical Criteria for Approval	
	Risperdal (risperidone)* Risperidone ODT^/risperidone ODT Saphris (asenapine)* Secuado (asenapine) Seroquel (quetiapine)* Versacloz (clozapine)	
	*generic available ^ branded generic product	
	Target Agent(s) will be approved when ONE of the following is met:	
	 The request is for Abilify (aripiprazole) AND ONE of the following: A. The patient has a medication history of use in the past 365 days, intolerance, or hypersensitivity to ONE generic antidepressant agent (i.e., SSRI, SNRI, bupropion, mirtazapine, or vilazodone), generic haloperidol, or pimozide OR B. The patient has an FDA labeled contraindication to ALL generic antidepressant agents (i.e., SSRI, SNRI, bupropion, mirtazapine, and vilazodone), haloperidol, and pimozide OR The request is for Abilify Mycite, Rexulti, Seroquel XR, or Vraylar AND ONE of the following: A. The patient has a medication history of use in the past 365 days, intolerance, or hypersensitivity to ONE generic antidepressant agent (i.e., SSRI, SNRI, bupropion, mirtazapine, or vilazodone) OR 	
	 B. The patient has an FDA labeled contraindication to ALL generic antidepressants (i.e., SSRI, SNRI, bupropion, mirtazapine, and vilazodone) OR 3. The request is for Zyprexa or Zyprexa Zydis AND ONE of the following: A. The patient has a medication history of use in the past 365 days, intolerance, or hypersensitivity to ONE generic fluoxetine OR 	
	 B. The patient has an FDA labeled contraindication to ALL generic fluoxetine OR 4. The patient has been treated with the requested agent within the past 180 days OR 5. The prescriber states the patient has been treated with the requested agent within the past 180 days AND is at risk if therapy is changed OR 	
	 The patient has a medication history of use in the past 365 days, intolerance, or hypersensitivity to ONE generic atypical antipsychotic OR The patient has an FDA labeled contraindication to ALL generic atypical antipsychotics OR The patient is currently being treated with the requested agent as indicated by ALL of the following: A statement by the prescriber that the patient is currently taking the requested agent AND 	
	 B. A statement by the prescriber that the patient is currently receiving a positive therapeutic outcome on requested agent AND C. The prescriber states that a change in therapy is expected to be ineffective or cause harm OR 	
	 The patient has an intolerance or hypersensitivity to a prerequisite agent OR The patient has an FDA labeled contraindication to ALL prerequisite agents OR The prescriber has provided documentation that ALL prerequisite agents cannot be used due to a documented medical condition or comorbid condition that is likely to cause an adverse reaction, decrease ability of the patient to achieve or maintain reasonable functional ability in performing daily activities or cause physical or mental harm 	
	Length of Approval: For dementia-related psychosis: 3 months for initial approval; 6 months for renewals	
	For all other indications: 12 months	
	NOTE: If Quantity Limit applies, please refer to Quantity Limit Criteria.	

QUANTITY LIMIT CLINICAL CRITERIA FOR APPROVAL

Module	Clinical Criteria for Approval	
	Quantity limit for the Target Agent(s) will be approved when ONE of the following is met:	
	The requested quantity (dose) does NOT exceed the program quantity limit OR	

Module	Clinical Criteria for Approval		
	The requested quantity (dose) exceeds the program quantity limit AND ONE of the following:		
	 A. BOTH of the following: 1. The requested agent does NOT have a maximum FDA labeled dose for the requested indication AND 2. There is support for therapy with a higher dose for the requested indication OR B. BOTH of the following: 1. The requested quantity (dose) does NOT exceed the maximum FDA 		
	labeled dose for the requested indication AND 2. There is support why the requested quantity (dose) cannot be achieved with a lower quantity of a higher strength that does NOT exceed the program quantity limit OR		
	 C. BOTH of the following: 1. The requested quantity (dose) exceeds the maximum FDA labeled dose for the requested indication AND 2. There is support for therapy with a higher dose for the requested indication 		
	Length of Approval: up to 12 months		